Economic burden of patients with leading cancers in China: a cost-of-illness study.

ABSTRACT:

Background

China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China.

Methods

This cross-sectional cost-of-illness study analyzed patients diagnosed with lung, breast, colorectal, esophageal, liver, or gastric cancer, identified through electronic health records (EHRs) from 84 hospitals across 17 provinces in China. Patients completed any one of the initial treatment phase, follow-up phase, and relapse/metastasis phase were recruite

SUBMITTER: Wu Z 

PROVIDER: S-EPMC11429825 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature